Tag
This study evaluates the safety and effectiveness of onabotulinumtoxinA doses above 400 units for upper and lower limb spasticity, showing no new safety concerns and suggesting clinical benefits.
This large cohort study demonstrates that biologic therapy in pregnant women with psoriasis is not associated with increased adverse pregnancy outcomes and may reduce risks of spontaneous abortion and gestational diabetes.
PHH-1V, a protein-based COVID-19 vaccine, is shown to be a safe and effective heterologous booster in adolescents, generating strong and lasting immune responses against multiple virus variants.
The AMETHYST Phase 2 trial demonstrated that litifilimab significantly improves skin symptoms in cutaneous lupus erythematosus with a favorable safety profile, marking a potential new targeted treatment for this challenging condition.
Lisocabtagene maraleucel shows sustained high remission rates and a favorable long-term safety profile in patients with heavily pretreated follicular lymphoma after three years of follow-up, including high-risk subgroups.
This multicenter RCT demonstrates that contrast-enhanced ultrasound (CEUS)-guided biopsy surpasses conventional US- and CT-guided modalities in diagnostic yield, sensitivity, and safety for subpleural lung lesions, highlighting its clinical
This review synthesizes phase 2 and 3 trial data demonstrating that the pentavalent MenABCWY vaccine is immunologically non-inferior and well tolerated compared with MenB-fHbp and MenACWY-CRM vaccines, offering a simplified, effective vacci
This phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.
Erythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control r
This review examines the safety and effectiveness of electronic cigarettes as aids to quit smoking, showing increased abstinence rates compared to traditional therapies and no significant serious adverse events reported.
A pooled individual‑patient meta‑analysis (6056 participants) shows single low‑dose primaquine (0.25 mg/kg) added to ACTs reduces gametocyte carriage and mosquito infectivity across ages and transmission settings without increasing clinical
A phase 1 trial of the rVSV‑vectored Lassa vaccine demonstrated dose-dependent transient reactogenicity, no vaccine‑related serious adverse events or hearing loss, and robust, durable humoral and cellular responses across doses and lineages
RSV vaccines demonstrate substantial effectiveness and acceptable safety profiles in adults aged ≥60, with diminished effectiveness in immunocompromised subgroups and a low, statistically significant increased risk of Guillain-Barré syndrom
A comprehensive evaluation of nearly five years of esketamine nasal spray use confirms its safety profile consistent with clinical trials, with no new safety signals detected in over 1.4 million treatment sessions.
This study evaluates factors influencing vasopressor route choice in sepsis and demonstrates low complication rates associated with peripheral administration, supporting its safety in early resuscitation.
The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious advers
This phase I study demonstrates that DEP-SN38, a dendrimer-nanoparticle conjugate of SN38, is well tolerated with minimal gastrointestinal toxicity and shows encouraging antitumor activity in heavily pretreated advanced solid tumors.
Epaminurad significantly lowers serum urate levels in gout patients with excellent safety, offering a promising alternative to existing therapies. This randomized controlled trial identifies optimal dosing and confirms tolerability over 12
A large retrospective study of over 524,000 patients found no increased risk of tachycardia associated with low-dose oral minoxidil (≤5 mg/day) for nonscarring hair loss, supporting its cardiac safety profile in patients without preexisting
Pre-stroke low-dose aspirin in distal medium vessel occlusion stroke patients undergoing mechanical thrombectomy is linked to improved 90-day functional outcomes and reduced mortality without increased symptomatic hemorrhage risk.
